IRIS
AMODIO, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.185
AS - Asia 3.136
EU - Europa 1.378
SA - Sud America 617
AF - Africa 53
Continente sconosciuto - Info sul continente non disponibili 16
OC - Oceania 6
Totale 9.391
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.057
SG - Singapore 1.518
CN - Cina 756
IT - Italia 668
BR - Brasile 483
VN - Vietnam 306
IN - India 277
SE - Svezia 202
GB - Regno Unito 132
DE - Germania 111
CA - Canada 85
HK - Hong Kong 69
AR - Argentina 51
FI - Finlandia 48
BD - Bangladesh 33
MX - Messico 28
RO - Romania 28
EC - Ecuador 26
IQ - Iraq 25
ID - Indonesia 23
RU - Federazione Russa 23
NL - Olanda 22
PL - Polonia 21
UA - Ucraina 21
CL - Cile 20
JP - Giappone 17
FR - Francia 16
ES - Italia 15
EU - Europa 15
CZ - Repubblica Ceca 13
EG - Egitto 13
PK - Pakistan 13
PY - Paraguay 13
TR - Turchia 13
ZA - Sudafrica 13
VE - Venezuela 11
JO - Giordania 10
AT - Austria 9
IR - Iran 9
AE - Emirati Arabi Uniti 8
MY - Malesia 7
UZ - Uzbekistan 7
KE - Kenya 6
LT - Lituania 6
SA - Arabia Saudita 6
AU - Australia 5
CH - Svizzera 5
CO - Colombia 5
GR - Grecia 5
NP - Nepal 5
YE - Yemen 5
DO - Repubblica Dominicana 4
EE - Estonia 4
HR - Croazia 4
IE - Irlanda 4
IL - Israele 4
MA - Marocco 4
MD - Moldavia 4
PH - Filippine 4
TN - Tunisia 4
DZ - Algeria 3
KZ - Kazakistan 3
PA - Panama 3
PE - Perù 3
RS - Serbia 3
SN - Senegal 3
SY - Repubblica araba siriana 3
UY - Uruguay 3
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
DK - Danimarca 2
ET - Etiopia 2
GE - Georgia 2
HN - Honduras 2
KW - Kuwait 2
LB - Libano 2
NO - Norvegia 2
SI - Slovenia 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
BO - Bolivia 1
BY - Bielorussia 1
CG - Congo 1
CR - Costa Rica 1
CV - Capo Verde 1
CY - Cipro 1
GY - Guiana 1
HU - Ungheria 1
JM - Giamaica 1
KH - Cambogia 1
KR - Corea 1
LV - Lettonia 1
MK - Macedonia 1
MN - Mongolia 1
NG - Nigeria 1
NR - Nauru 1
PR - Porto Rico 1
PT - Portogallo 1
Totale 9.387
Salva come PNG Salva come JPEG
Città #
San Jose 909
Singapore 501
Chandler 388
Ashburn 383
Santa Clara 256
Dallas 235
Hefei 225
Bengaluru 219
Milan 196
Lawrence 189
Princeton 189
Beijing 177
Catanzaro 139
Ho Chi Minh City 131
Wilmington 106
Chicago 90
London 90
Munich 84
Hong Kong 69
Hanoi 60
Des Moines 57
Ottawa 47
São Paulo 46
Los Angeles 44
Boardman 36
Turku 34
Rio de Janeiro 26
Shanghai 24
New York 23
Haiphong 22
Brooklyn 21
Redwood City 20
Rome 20
Warsaw 19
Council Bluffs 16
Guangzhou 16
San Francisco 16
Helsinki 14
Horia 14
Montreal 14
Phoenix 14
Pune 14
The Dalles 14
Da Nang 13
Naples 13
Norwalk 13
Olomouc 12
Stockholm 12
Baghdad 11
Bari 11
Boston 11
Hanover 10
Manchester 10
Redmond 10
Timisoara 10
Amman 9
Cosenza 9
Curitiba 9
Mexico City 9
Tokyo 9
Chennai 8
Columbus 8
Dhaka 8
Parma 8
Porto Alegre 8
Quito 8
Reggio Calabria 8
Ann Arbor 7
Biên Hòa 7
Charlotte 7
Guayaquil 7
Jiaxing 7
Johannesburg 7
Lamezia Terme 7
Orem 7
Ovada 7
San Nicola Manfredi 7
Santiago 7
Settingiano 7
Shenzhen 7
Tashkent 7
Amsterdam 6
Atlanta 6
Belo Horizonte 6
Nairobi 6
Palermo 6
Salvador 6
Thái Bình 6
Toronto 6
Uberlândia 6
West Jordan 6
Andover 5
Ankara 5
Augusta 5
Aversa 5
Campinas 5
Caracas 5
Caserta 5
Contagem 5
Florianópolis 5
Totale 5.647
Salva come PNG Salva come JPEG
Nome #
miR-22 suppresses DNA ligase III addiction in multiple myeloma 103
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. 99
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells 89
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells in vitro 86
Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease 86
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 83
Mitochondrial dysfunction at the crossroad of cardiovascular diseases and cancer 80
IL-6 Receptor Blockade by Tocilizumab Has Anti-absence and Anti-epileptogenic Effects in the WAG/Rij Rat Model of Absence Epilepsy 78
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. (CO-FIRST AUTHOR) 75
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 74
Discovery, Functional Characterization and Therapeutic Targeting of Lnc-17-92 Metabolic Signaling in Multiple Myeloma 73
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 73
Early hematopoietic zinc finger protein (EHZF), the human homolog to mouse Evi3, is highly expressed in primitive human hematopoietic cells 72
LNA-Gapmer Antisense Oligonucleotides Targeting the Oncogenic Lncrna MALAT1 Trigger Anti-Multiple Myeloma Activity By Proteasome Blockade 71
MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence 70
Effects of Histone Deacetylase Inhibitors on the Development of Epilepsy and Psychiatric Comorbidity in WAG/Rij Rats 70
Turning Stem Cells Bad: Generation of Clinically Relevant Models of Human Acute Myeloid Leukemia through Gene Delivery- or Genome Editing-Based Approaches 69
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma 69
Radiation induced by-stander effect: possible RNA implication in DNA damage transmission? 67
Early Hematopoietic Zinc Finger protein (EHZF), the human homologue to Evi3, is highly expressed in primitive human hematopoietic cells 67
Molecular and clinical types of plasma cell dyscrasias are associated with distinct expression patterns of long noncoding RNAs 66
Jagged ligands enhance the pro-angiogenic activity of multiple myeloma cells 65
In Vitro Silencing of lncRNAs Using LNA GapmeRs 65
Oleil hydroxytyrosol (Htol) exerts anti-myeloma activity by antagonizing key survival pathways in malignant plasma cells (CO-FIRST AUTHOR) 65
A Comparison of Different Sample Processing Protocols for MALDI Imaging Mass Spectrometry Analysis of Formalin-Fixed Multiple Myeloma Cells 64
Ex-vivo characterization of circulating colon cancer cells distinguished in stem and differentiated subset provides useful biomarker for personalized metastatic risk assessment 64
Impact of natural dietary agents on multiple myeloma prevention and treatment: molecular insights and potential for clinical translation. 64
MIR-21 SUPPRESSION IMPAIRS TH17 RELATED BONE DISEASE IN MULTIPLE MYELOMA 64
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 64
ACTIVATION OF GPER SIGNALING AS A POTENTIAL THERAPEUTIC STRATEGY AGAINST WALDENSTROM MACROGLOBULINEMIA 63
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 63
Early hematopoietic zinc finger protein, a novel transcription co-factor with a potential role in haematopoietic homeostasis and leukaemogenesis 62
ZNF423: A New Player in Estrogen Receptor-Positive Breast Cancer 61
Anti-MALAT1 synthetic oligonucleotides target the proteasome and exert anti-multiple myeloma activity 61
ZNF423: A New Player in Estrogen Receptor-Positive Breast Cancer. 61
Contribution of PKB/AKT signaling to thyroid cancer 61
Cateslytin abrogates lipopolysaccharide-induced cardiomyocyte injury by reducing inflammation and oxidative stress through toll like receptor 4 interaction 61
Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against Waldenstrom Macroglobulinemia 60
P21-ACTIVATED KINASE 4 (PAK4) REGULATES MULTIPLE MYELOMA (MM) CELL GROWTH AND SURVIVAL BY MODULATION OF CRITICAL TRANSCRIPTIONAL PATHWAYS: THERAPEUTIC APPLICATION OF PAK4 ALLOSTERIC INHIBITORS 60
A MIR17HG-derived Long Noncoding RNA Provides an Essential Chromatin Scaffold for Protein Interaction and Myeloma Growth 59
Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation 59
MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment 59
A 13 mer LNA miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells 59
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells (CO-FIRST AUTHOR) 58
CRISPR Interference (CRISPRi) and CRISPR Activation (CRISPRa) to Explore the Oncogenic lncRNA Network 58
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 57
TARGETING OF DEREGULATED LNCRNA NEAT1 AFFECTS MULTIPLE MYELOMA ACTIVITY 57
A Comparison of Different Sample Processing Protocols for MALDI Imaging Mass Spectrometry Analysis of Formalin-Fixed Multiple Myeloma Cells 56
Synthesis and preliminary evaluation of the anti-cancer activity on A549 lung cancer cells of a series of unsaturated disulfides. 56
Zinc finger protein 521 antagonizes early B-cell factor 1 and modulates the B-lymphoid differentiation of primary hematopoietic progenitors 56
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 56
Early hematopoietic zinc finger protein - zinc finger protein 521 (EHZF/ZNF521): a candidate regulator of diverse immature cells 56
Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. 56
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma 55
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: In vitro and in vivo anti-tumor activity 55
Selective Activation of the Non-Classical Estrogen Receptor Gper Elicits Potent Anti-Tumor Activity in Multiple Myeloma 55
Alternative non-homologous end joining DNA repair as therapeutic target in multiple myeloma 55
The non-coding RNA landscape of plasma cell dyscrasias 55
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma 54
Znf521 enhances mll‐af9‐dependent hematopoietic stem cell transformation in acute myeloid leukemias by altering the gene expression landscape† 54
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia 53
In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma 53
Inhibitor of DNA binding 2 (ID2) regulates key transcriptional programs in multiple myeloma 53
Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity 52
Activating E17K mutation in the gene encoding the protein kinase B/AKT in squamous cell carcinoma of the lung 52
Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma 52
The chromogranin A1-373 fragment reveals how a single change in the protein sequence exerts strong cardioregulatory effects by engaging neuropilin-1 52
Early hematopoietic zinc finger protein prevents tumor cell recognition by natural killer cells 52
Targeting of mitochondrial fission through natural flavanones elicits anti-myeloma activity (CO-FIRST AUTHOR) 51
ZINC FINGER PROTEIN 521 (EHZF/ZNF521) ANTAGONIZES EARLY B-CELL FACTOR 1 AND MODULATES THE B-LYMPHOID DIFFERENTIATION OF PRIMARY HEMATOPOIETIC PROGENITORS 51
Non-coding RNA: A novel opportunity for the personalized treatment of multiple myeloma 51
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. 50
Synthetic MiR-29b Mimics Potentiate Dendritic-Cell Based Immunotherapy Against Multiple Myeloma In Vitro and In Vivo 50
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity 50
Arginine Methylation Mediated By PRMT5 Has Significant Biological and Clinical Impact in Multiple Myeloma 49
Biological Insights into Myeloma and Other B Cell Malignancies 49
Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth 48
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies 48
Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence 48
Receptor identification and physiological characterisation of glucagon-like peptide-2 in the rat heart 48
Phoenixin-14: detection and novel physiological implications in cardiac modulation and cardioprotection 48
Protective role of GPER agonist g-1 on cardiotoxicity induced by doxorubicin 48
Natural Agents as Novel Potential Source of Proteasome Inhibitors with Anti-Tumor Activity: Focus on Multiple Myeloma 47
Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment. 47
miR-22 suppresses DNA ligase III addiction in multiple myeloma. 47
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity 47
Palmitate-Induced Cardiac Lipotoxicity Is Relieved by the Redox-Active Motif of SELENOT through Improving Mitochondrial Function and Regulating Metabolic State 47
Contribution of PKB/AKT signaling to thyroid cancer 46
In vitro and vivo activity against multiple myeloma cells of a novel locked nucleic acid (LNA)-miR-221 inhibitor 46
Hit Identification and Functional Validation of Novel Dual Inhibitors of HDAC8 and Tubulin Identified by Combining Docking and Molecular Dynamics Simulations 45
From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario 45
Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation 45
Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma 45
Early Hematopoietic Zinc Finger (EHZF/ZNF521) prevents tumor cell recognition by Natural Killer Cells 45
Inhibition Of Mir-21 In HS-5 Bone Marrow Stromal Cells In The Presence Of Multiple Myeloma cells Restores RANKL/OPG Ratio: A Potential Therapeutic Approach For Myeloma-Related Bone Disease 44
Tumor Suppressor MiR-29b Targets HDAC4 and Modulates Vorinostat Activity In Multiple Myeloma Cells 44
Expression pattern and biological significance of the lncRNA ST3GAL6-AS1 in multiple myeloma 44
CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents 43
Early Hematopoietic Zinc Finger protein (EHZF), a novel co-transcription factor: functional properties, expression in myelogenous leukaemias and interactions with histone deacetylases 43
In vitro expansion of tumour cells derived from blood and tumour tissue is useful to redefine personalized treatment in non-small cell lung cancer patients 43
Totale 5.854
Salva come PNG Salva come JPEG
Categoria #
all - tutte 99.542
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 99.542
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202127 0 0 0 0 0 0 0 0 0 0 0 27
2021/2022569 23 2 5 154 38 13 24 113 54 61 71 11
2022/20231.183 386 64 71 68 100 93 5 87 163 51 70 25
2023/2024515 113 73 34 42 28 129 13 8 2 14 19 40
2024/20252.129 321 95 65 58 151 302 44 51 266 130 214 432
2025/20264.676 264 494 445 773 518 181 604 275 639 324 132 27
Totale 9.652